Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Sees Atrasentan Market Opportunity In Less Advanced Prostate Cancer

Executive Summary

Abbott sees a market opportunity for atrasentan in prostate cancer patients with less advanced disease based on the company's initial subset analysis of an unfavorable Phase III study for the endothelin-1 receptor antagonist

You may also be interested in...



Abbott Xinlay Review By Oncologic Committee Expected In Mid-September

Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September

Abbott Xinlay Review By Oncologic Committee Expected In Mid-September

Review of Abbott's Xinlay by FDA's Oncologic Drugs Advisory Committee for treatment of metastatic hormone-refractory prostate cancer will likely take place in mid-September

AstraZeneca Sets Two NMEs Per Year As Metric Of R&D Success

AstraZeneca is setting a goal of launching two new molecular entities each year, Exec VP-Global Drug Development Martin Nicklasson, PhD, said Feb. 10 at a drug development summit sponsored by R&D Directions in Phoenix

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel